Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Twenty First Century Health

This article was originally published in The Gray Sheet

Executive Summary

Twenty First Century Health: Las Vegas-based firm resumes trading on the OTC Bulletin Board Feb. 25 following a ten-day suspension stemming from an ongoing inquiry by the Securities and Exchange Commission into the firm's non-invasive glucose meter technology and other financial issues. SEC questions "the adequacy and accuracy of publicly disseminated information" relating to: TFCH's financial condition; the existence, effectiveness and marketability of TFCH's glucose monitor and its potential market; and "the ownership, value and business of certain companies purportedly acquired by TFCH," the agency states. TFCH says it plans to fully comply with the investigation by completing an audit report and submitting other requisite financial material to the National Association of Securities Dealers. TFCH also notes it plans to submit to FDA a 510(k) for the glucose monitor...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel